Form 4: BioAtla CFO's Stock Withholding for Tax Obligations

BioAtla's Chief Financial Officer, Richard A. Waldron, had 2,371 shares withheld by the company to cover tax obligations related to restricted stock unit vesting.

Summary

• Richard A. Waldron, Chief Financial Officer of BioAtla, Inc. (BCAB), reported a transaction involving company common stock.
• On August 31, 2025, 2,371 shares of BioAtla common stock were withheld by the Issuer.
• This withholding was to satisfy income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.
• The transaction is explicitly stated not to be a sale of shares by Mr. Waldron.
• The price per share for the withheld shares was $0.4555.
• Following this transaction, Mr. Waldron directly beneficially owns 338,521 shares of BioAtla common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine administrative transaction where shares were withheld to cover tax obligations related to restricted stock unit vesting, which is a neutral event for the company's operational or financial performance.

Positives

• The vesting of restricted stock units (RSUs) for the Chief Financial Officer indicates the fulfillment of compensation incentives, aligning management's interests with shareholder value over time.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation-related event, reflecting the ongoing executive compensation structure.
• Employees: The vesting of restricted stock units is a positive for the executive, demonstrating the realization of long-term incentives.

Key Dates

Recommendation

This Form 4 details a routine administrative transaction where shares were withheld to cover tax obligations upon the vesting of restricted stock units for a company officer. Such a transaction is a standard part of executive compensation and does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation.

Keywords

BioAtla, BCAB, Richard A. Waldron, Chief Financial Officer, CFO, Form 4, SEC filing, stock transaction, restricted stock units, RSU, tax withholding, insider transaction